An amino acid residue whose change by mutation affects drug binding to the HERG channel [PDF]
Kuniaki Ishii+4 more
openalex +1 more source
Self-assembling dendrimer nanodrug formulations for decreased hERG-related toxicity and enhanced therapeutic efficacy. [PDF]
Liu X+18 more
europepmc +1 more source
Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine [PDF]
Ashok A Paul+2 more
openalex +1 more source
FDA's insights: implementing new strategies for evaluating drug-induced QTc prolongation. [PDF]
Ji Y, Johannesen L, Garnett C.
europepmc +1 more source
IRAK1/4/pan-FLT3 Kinase Inhibitors with Reduced hERG Block as Treatments for Acute Myeloid Leukemia. [PDF]
Hoyt SB+24 more
europepmc +1 more source
Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels [PDF]
Jun Chen+2 more
openalex +1 more source
Molecular insights into the rescue mechanism of an HERG activator against severe LQT2 mutations. [PDF]
Kumawat A+8 more
europepmc +1 more source
[3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen
Keith Finlayson+4 more
openalex +1 more source
Recent advances in AI-based toxicity prediction for drug discovery. [PDF]
Lee H, Kim J, Kim JW, Lee Y.
europepmc +1 more source